Abstract
Objective The purpose of this study was to investigate the relationship between imaging and the multivariate index assay (MIA) in the prediction of the likelihood of ovarian malignancy before surgery. Study Design Subjects were recruited in 2 related prospective, multiinstitutional trials that involved 44 sites across the United States. Women had ovarian imaging, biomarker analysis, and surgery for an adnexal mass. Ovarian tumors were classified as high risk for solid or papillary morphologic condition on imaging study. Biomarker and imaging results were correlated with surgical findings. Results Of the 1110 women who were enrolled with an adnexal mass on imaging, 1024 cases were evaluable. There were 255 malignant and 769 benign tumors. High-risk findings were present in 46% of 1232 imaging tests and 61% of 1024 MIA tests. The risk of malignancy increased with rising MIA scores; similarly, the likelihood of malignancy was higher for high-risk, compared with low-risk, imaging. Sensitivity and specificity for the prediction of malignancy were 98% (95% CI, 92-99) and 31% (95% CI, 27-34) for ultrasound or MIA; 68% (95% CI, 58-77) and 75% (95% CI, 72-78) for ultrasound and MIA, respectively. For computed tomography scan or MIA, sensitivity was 97% (95% CI, 92-99) and specificity was 22% (95% CI, 16-28); the sensitivity and specificity for computed tomography scan and MIA were 71% (95% CI, 62-79) and 70% (95% CI, 63-76). Only 1.6% of ovarian tumors were malignant when both tests indicated low risk. A logistic regression model to predict risk of malignancy is presented. Conclusion An understanding of how pelvic imaging influences the MIA score can help clinicians better interpret the malignant risk of an ovarian tumor.
Original language | English |
---|---|
Pages (from-to) | 65.e1-65.e11 |
Journal | American Journal of Obstetrics and Gynecology |
Volume | 211 |
Issue number | 1 |
DOIs | |
State | Published - Jul 2014 |
Bibliographical note
Funding Information:S.T.G. and J.T.S. are members of the Vermillion Inc speakers bureau. R.E.B. was the principal investigator for the OVA500 trial and has been a member of the Vermillion Inc speakers bureau because November 2011. He has not received honoraria from Vermillion Inc. A.S. is Vice-President, Biometrics, at Applied Clinical Intelligence and is a consultant for Vermillion Inc. Z.Z. is coinventor of patents associated with the OVA1 product and is entitled to royalty payments from the OVA1 test through a license agreement between Vermillion Inc and Johns Hopkins University. His work on OVA1 has been funded through sponsored research agreements between Vermillion Inc and Johns Hopkins University. F.R.U. was the principal investigator for the OVA1 trial. He is a member of Vermillion Inc speakers bureau and has received speaking honoraria from Vermillion Inc. R.W.M. reports no conflict of interest.
Keywords
- OVA1
- imaging
- multivariate index assay
- ovarian tumor
ASJC Scopus subject areas
- Obstetrics and Gynecology